Big biotech, Big pharma, Biotech, Partnering, Pharma

Illumina join hands with AstraZeneca, Janssen Biotech and Sanofi

Posted on 22 August 2014

Tags: , , , , ,

Illumina has formed a collaborative partnership with leading pharmaceutical companies AstraZeneca, Janssen Biotech and Sanofi.

The collaborative partnership aims to develop a paradigm-shifting universal next-generation sequencing (NGS)-based system for oncology research and drug development.

Once Illumina achieves regulatory approval, the company will commercialize the system.

Thus far, cancer researchers have identified 125 cancer driver genes—71 tumor suppressors and 54 oncogenes—that lead to tumor growth via 12 cellular signaling pathways.

The rise of targeted drugs requires more accurate, and specific, diagnostic testing—which is what Illumina wants to achieve with its new universal NGS-based test system.

For further deal information visit Current Agreements (subscription required)

Related

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply